NewAmsterdam Pharma Q2 net loss widens to USD 64.1 million; revenue falls to USD 3.7 million
NAMS•Second-quarter results widen loss
- NewAmsterdam Pharma posted a 2Q net loss of USD 64.1 million, widening from USD 17.4 million a year earlier.
- Revenue fell 80.66% year over year to USD 3.7 million.
- R&D expenses climbed 51.64% to USD 41.7 million, while SG&A costs edged down 1.36% to USD 26.9 million.
- Cash, cash equivalents and marketable securities totaled USD 678.3 million at June 30, 2026, down from USD 728.9 million at Dec. 31, 2025.
Regulatory update and pipeline timing
- The CHMP issued a positive opinion for obicetrapib and an obicetrapib/ezetimibe fixed-dose combination.
- PREVAIL interim analysis is planned for 4Q 2026.
